Challenger (CGF) H1 2026 earnings summary

Executive summary

• Statutory NPAT rose to AUD 339 million in H1 2026, up 369% year-over-year, with normalized NPAT up 2% to AUD 229 million and normalized EPS up 2% to 33.3cps; interim dividend increased 7% to 15.5cps, fully franked.

• Record annuity sales of AUD 3.8 billion (+32%) and total Life sales up 11% to AUD 5.1 billion, supported by demographic tailwinds and growth in both domestic and offshore markets.

• Strategic initiatives included technology transformation, new partnerships, expansion of offshore reinsurance (notably in Asia), and acquisition of a 22% stake in Fulcrum Asset Management.

• Announced a proposed AUD 150 million on-market buyback, reflecting capital strength and flexibility, and S&P upgraded credit ratings for CLC and Challenger Limited.

• Benefited from structural growth in Australia’s superannuation system and regulatory reforms supporting retirement income products.

Financial highlights

• Statutory NPAT: AUD 339 million (+369%); normalized NPAT: AUD 229 million (+2%); normalized EPS: 33.3cps (+2%).

• Group net income increased 1% to AUD 487 million; cost-to-income ratio improved to 31.7%, a record low and below the 32%-34% target range.

• Book growth of 5.8% and annuity book growth of 7.4% drove a 5% increase in average investment assets.

• Funds Management NPAT up 7% to AUD 29 million, with alternatives now 15% of Fidante's FUM.

• Group AUM at AUD 128.2 billion, down 2.4% year-over-year due to net outflows in Funds Management.

Outlook and guidance

• FY26 normalized basic EPS guidance reaffirmed at 66–72cps, with H1 at 33.3cps; group NPAT expected between AUD 455 million and AUD 495 million.

• Through-the-cycle targets for ROE, cost-to-income, and capital remain unchanged.

• Anticipates a shift in asset allocation toward fixed income and lower capital intensity as new APRA capital standards take effect from July 2026.

• Dividend payout ratio targeted at 30%-50%.